4 ms·
Friends in the pharma and medical device development industry have told me that the business case for any drug or medical device is built on top of US sales at
by danans 10y ago
Friends in the pharma and medical device development industry have told me that the business case for any drug or medical device is built on top of US sales at currently inflated US prices.
According to them, the other developed countries that have negotiated lower rates for drugs serve a different purpose. Those countries have lower requirements around testing of drugs and medical devices, and they are able to move to human trials and market sooner there. The trade-off for those countries is slightly higher risk of sub-optimal outcomes, but this appears to be more accepted by the populations of those countries than it is by Americans.
I'm not writing this to vouch for this setup - it seems like it is pretty unbalanced and ultimately does a lot of harm to people in the US due to drug inaccessibility - but I thought I'd share it for another perspective.
- _acme 10y agoDo you have support for the claim that US-developed drugs are generally available sooner in non-US markets? My understanding was that these drugs are generally available first in the US market, but that the developers may use FDA approval to help with EU approval, etc.
- danans 10y agoIn the case of the medical device company in question, the trials took place in Europe due to an easier regulatory process around testing. As I said, it's their personal story, but here is an article that describes the differences between the systems: http://www.nejm.org/doi/full/10.1056/NEJMhle1113918#t=article http://www.nejm.org/doi/full/10.1056/NEJMhle1113918#t=articl... I didn't mean to imply that US drug prices necessarily have anything to do with its regulatory structure, or that the European regulatory structure had anything to do with their prices, only that the companies have probably optimized their development and pricing strategies for the economic and political situations in the local markets.
- dodgedcactii 10y agoSame execs that probably sell you a line about R&D costs, right? Not sure why you'd ever trust them to speak truthfully about delivering good health to Americans.